By Abigail Klein Leichman Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe COVID-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial. Study results, soon to be published, show MesenCure treatment reduced study participants’ hospitalization period by about half compared to a […]
